NCCN Guidelines® Insights
Thyroid Carcinoma, Version 2.2018
Featured Updates to the NCCN Guidelines

Robert I. Haddad, MD1,2; Christian Nasr, MD1; Lindsay Biscoff, MD1; Naifa Lamki Busaidy, MD1; David Byrd, MD1; Glenda Callender, MD1; Paxton Dickson, MD1; Quan-Yang Duh, MD1; Hormoz Ehya, MD1; Whitney Goldner, MD1,2; Dominick M. Lamonica, MD1; Bryan McIver, MD, PhD1,2; Christopher D. Raeburn, MD1; John A. Ridge, MD, PhD1; Matthew D. Ringel, MD2; Randall P. Scheri, MD1; Jatin P. Shah, MD, PhD2; Rebecca Sippel, MD2,3; Robert C. Smallridge, MD2; Cord Sturgeon, MD2; Thomas N. Wang, MD, PhD2; Lori J. Wirth, MD2,3; Richard J. Wong, MD2; Alyse Johnson-Chilla, MS2; and Lisa A. Gurski, PhD2,3.

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel’s discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines is available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

1Dana-Farber/Brigham and Women’s Cancer Center; 2Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 3Vanderbilt-Ingram Cancer Center; 4The University of Texas MD Anderson Cancer Center; 5University of Washington/Seattle Cancer Care Alliance; 6Yale Cancer Center/Smilow Cancer Hospital; 7St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; 8UCSF Helen Diller Family Comprehensive Cancer Center; 9Fox Chase Cancer Center; 10Fred & Pamela Buffett Cancer Center; 11University of Michigan Rogel Cancer Center; 12UC San Diego Moores Cancer Center; 13Huntsman Cancer Institute at the University of Utah; 14Stanford Cancer Institute; 15City of Hope National Medical Center; 16Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 17Roswell Park Comprehensive Cancer Center; 18Moffitt Cancer Center; 19University of Colorado Cancer Center; 20The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute; 21Duke Cancer Institute; 22Memorial Sloan Kettering Cancer Center; 23University of Wisconsin Carbone Cancer Center; 24Mayo Clinic Cancer Center; 25University of Alabama at Birmingham Comprehensive Cancer Center; 26Massachusetts General Hospital Cancer Center; and 27National Comprehensive Cancer Network.

*Provided content development and/or authorship assistance.
NCCN: Continuing Education

Target Audience: This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Accreditation Statement NCCN

Physicians: National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists: National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-012-H01-P

Disclosure of Relevant Financial Relationships

The NCCN staff listed below discloses no relevant financial relationships:

Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Eamberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield, RN, OCN; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:

Robert I. Haddad, MD, Panel Chair; has disclosed that he receives grant/research support from Merck & Co., Inc., Bristol-Myers Squibb Company, Genentech, Inc., and Pfizer Inc. He also receives consulting fees/honoraria from Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Celgene Corporation, Eisai Inc., AstraZeneca Pharmaceuticals LP, and Loxo Oncology, Inc.

Christian Nasr, MD, Panel Vice Chair; has disclosed that he receives consulting fees from Eisai Inc., Exelixis Inc., and Nevro Corp.; and that he receives honoraria from Shire plc and sanofi-aventis U.S. LLC.

Lindsay Bischoff, MD, Panel Member; has disclosed that she has no relevant financial relationships.

Hormoz Ehya, MD, Panel Member; has disclosed that he has no relevant financial relationships.

Whitney Goldner, MD, Panel Member; has disclosed that she has an other financial benefit from AstraZeneca Pharmaceuticals LP, Eisai Inc., Roche Laboratories, Inc.

Megan Haymart, MD, Panel Member; has disclosed that she has no relevant financial relationships.

Peter Kopp, MD, Panel Member; has disclosed that he has no relevant financial relationships.

Rebecca Sippel, MD, Panel Member; has disclosed that she has no relevant financial relationships.

Cord Sturgeon, MD, Panel Member; has disclosed that he has no relevant financial relationships.

Lori J. Wirth, MD, Panel Member; has disclosed that she serves as a scientific advisor for Ayala Pharmaceuticals, Inc.; Bayer Healthcare; Eisai Inc.; Loxo Oncology, Inc.; and Merck & Co., Inc.

Richard Wong, MD, Panel Member; has disclosed that he has no relevant financial relationships.

Alyse Johnson-Chilla, MS, Guidelines Coordinator, NCCN; has disclosed that she has no relevant financial relationships.

Karin G. Hoffmann, RN, CCM, Guidelines Coordinator, NCCN; has disclosed that she has no relevant financial relationships (employed by NCCN until 6/1/18).

Lisa A. Gurski, PhD, Oncology Scientist/Medical Writer, NCCN; has disclosed that she has no relevant financial relationships.

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/84621; and 3) view/print certificate.

Pharmacists: You must complete the posttest and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the posttest and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Your credit cannot be reported without this information. If you have any questions, please e-mail education@nccn.org.

Release date: December 10, 2018; Expiration date: December 10, 2019

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Integrate into professional practice the updates to the NCCN Guidelines for Thyroid Carcinoma
• Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Thyroid Carcinoma

This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE.
Overview

Thyroid nodules, often palpated during routine physical examination, are relatively common and increase in frequency throughout life, reaching a prevalence of approximately 5% of US individuals aged ≥50 years having palpable thyroid nodules.1–3 Nodules are even more prevalent when the thyroid gland is examined at autopsy or surgery, or when using ultrasonography; 50% of the thyroids studied have nodules, which are almost always benign.2,4 By contrast, thyroid carcinoma is uncommon. For the US population, the lifetime risk of being diagnosed with thyroid carcinoma is 1.2%,5 with an estimated 53,990 new cases of thyroid carcinoma being diagnosed in 2018.6 As with thyroid nodules, thyroid carcinoma occurs 2 to 3 times more often in women than in men and is currently the fifth most common malignancy diagnosed in women.6 The main histologic types of thyroid carcinoma are (1) differentiated thyroid carcinoma (DTC; including papillary, follicular, and Hurthle cell); (2) medullary thyroid carcinoma (MTC); and (3) anaplastic thyroid carcinoma (ATC). Of 63,324

---

**NCCN Guidelines Insights**

**CE**

**NCCN Guidelines Insights**

**CE**

**NCCN Categories of Evidence and Consensus**

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

**Clinical trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Version 2.2018 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved.**

The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
patients diagnosed with thyroid carcinoma from 2011 to 2015, 89.8% had papillary carcinoma, 4.5% had follicular carcinoma, 1.8% had Hürthle cell carcinoma, 1.6% had MTC, and 0.8% had ATC.3

Mortality rates for thyroid carcinoma are, in general, very low. DTC usually has an excellent prognosis, with 10-year survival rates exceeding 90% to 95%.7 In contrast, ATC, an aggressive undifferentiated tumor, is almost uniformly lethal. However, because DTCs represent >95% of all cases, most thyroid carcinoma deaths are from papillary, follicular, and Hürthle cell carcinomas. In 2018, it is estimated that approximately 2,060 cancer deaths will occur among persons with thyroid carcinoma in the United States.6 The stable age- and sex-adjusted mortality rate for thyroid carcinoma contrasts distinctly with the declining rates for other solid tumors in adults, and highlights the need for new treatment options for advanced thyroid cancers.5,8,9

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma provide recommendations for management of the different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, MTC, and ATC. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for DTC, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and the addition of a new targeted therapy option for BRAF V600E–mutated ATC.

**Molecular Testing for DTC**

Molecular testing for DTC may be conducted for diagnostic, prognostic, and/or predictive purposes. Because many thyroid cancers have an excellent prognosis and benign nodules are common, diagnostic or prognostic markers can be useful for evaluating suspicious thyroid nodules so that appropriate treatment options can be determined.1,10,11 Predictive markers,
used to guide treatment with specific targeted therapies, are increasingly being used (particularly within clinical trials) for advanced thyroid cancers. The following sections detail the NCCN panel’s discussions on the use of molecular markers for the diagnosis and treatment of thyroid cancer.

**Diagnostic/Prognostic Markers**

Fine-needle aspiration (FNA) with ultrasound guidance is the preferred procedure for evaluating suspicious thyroid nodules.\(^{3,11,12}\) FNA of clinically significant or suspicious cervical lymph nodes should also be considered if identified in the ultrasonographic evaluation of the thyroid and neck. Cytologic examination of an FNA specimen is typically categorized as:

- **Category I:** nondiagnostic or unsatisfactory biopsy;
- **Category II:** benign (ie, nodular goiter, colloid goiter, hyperplastic/adenomatoid nodule, Hashimoto’s thyroiditis);

- **Category III:** atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS);
- **Category IV:** follicular neoplasm or suspicious for follicular neoplasm (includes Hurthle cell neoplasm);
- **Category V:** suspicious for malignancy; or
- **Category VI:** malignancy (includes papillary, MTC, ATC or lymphoma).

These diagnostic categories for FNA results reflect the 2017 Bethesda System for Reporting Thyroid Cytopathology.\(^ {13} \)

Molecular diagnostic testing to detect individual mutations (eg, BRAF V600E, RET/PTC, RAS, PAX8/PPARY) or pattern recognition approaches using molecular classifiers may be useful in evaluating FNA samples that are indeterminate to assist in management decisions.\(^ {14–21} \) The BRAF V600E mutation occurs in approximately 45% of papillary carcinomas...
Thyroid Carcinoma, Version 2.2018

**METASTATIC DISEASE**

---

**Stage IVcc**

- Aggressive therapy
  - Total thyroidectomy with therapeutic lymph node dissection if resectable (R0/R1)
  - Locoregional radiation therapy
  - Systemic therapy (See ANAP-A)
  - Molecular testing for actionable mutations
  - Consider clinical trial

- Palliative care
  - Palliative locoregional radiation therapy
  - Local lesion control with surgery or radiation (eg, bone, brain metastases)
  - See NCCN Guidelines for Central Nervous System Cancers
  - Best supportive care

**SURVEILLANCE AND MANAGEMENT**

- Cross-sectional imaging (CT or MRI with contrast) of brain, neck, chest, abdomen, and pelvis at frequent intervals as clinically indicated.
- Consider FDG-PET-CT 3–6 months after initial therapy.
- Continued active surveillance if NED
  - Palliative locoregional radiation therapy
  - Local lesion control (eg, bone, brain metastases)
  - Second-line systemic therapy or clinical trial
  - See NCCN Guidelines for Palliative Care
  - Best supportive care

---

and is the most common mutation. Some studies have linked the BRAF V600E mutation to poor prognosis, especially when occurring with a TERT promoter mutation. Choice of the precise molecular test depends on the cytology and the clinical question being asked. Molecular diagnostic testing may include multigene assays (eg, a gene expression classifier [GEC]) or individual mutational analysis.

Rather than proceeding to immediate surgical resection to obtain a definitive diagnosis for these indeterminate FNA cytology groups (follicular neoplasm/suspicious for follicular neoplasm or AUS/FLUS), patients can be followed with active surveillance if the application of a specific molecular diagnostic test (in conjunction with clinical and ultrasound features) results in a predicted risk of malignancy that is comparable to the rate seen in cytologically benign thyroid FNAs (approximately ≤5%). It is important to note that the predictive value of molecular diagnostics may be significantly influenced by the pretest probability of disease associated with the various FNA cytology groups. Furthermore, in the cytologically indeterminate groups, risk of malignancy from FNA can vary widely between institutions. Therefore, proper implementation of molecular diagnostics into clinical care requires an understanding of both the performance characteristics of the specific molecular test and its clinical meaning across a range of pretest disease probabilities.

The NCCN panel discussed the use of molecular diagnostic testing for evaluating FNA results of follicular neoplasm/suspicious for follicular neoplasm or AUS/FLUS. Although most of the panel members agreed that they are using molecular diagnostics for this purpose, they expressed uncertainty regarding whether the testing was helpful in guiding treatment. Some panel members voiced concern that the structure of THYR-4 placed too much emphasis on the role of molecular diagnostics. Therefore, the algorithm on THYR-4 was restructured to deemphasize molecular diagnostic testing and to allow an option for active surveillance when molecular diagnostics are not performed for AUS/FLUS (page 1431). In addition, the
Severe or fatal side effects from kinase inhibitors may be required. Therefore, novel treatments for patients with metastatic DTCs that are not surgically resectable, are not amenable to radioactive iodine (RAI), and are progressing and/or symptomatic. Overall, traditional cytotoxic systemic chemotherapy, such as doxorubicin, has minimal efficacy in patients with metastatic DTC. Therefore, novel treatments for patients with metastatic DTC have been evaluated. Agents with documented efficacy in this setting include lenvatinib, sorafenib, sunitinib, axitinib, everolimus, vandetanib, cabozantinib, and pazopanib among others. Severe or fatal side effects from kinase inhibitors include bleeding, hypertension, stroke, and liver toxicity; however, most side effects can be managed and are reversible with discontinuation of the drug. Dose modifications of kinase inhibitors may be required.

Although the clinical use of predictive markers is currently limited for advanced thyroid cancers, recent data have shown that the BRAF inhibitors vemurafenib and dabrafenib can be effective treatment options for DTC harboring the BRAF V600E mutation. Because this mutation is common in papillary thyroid cancers, these therapies may be especially promising for this tumor type. An open-label nonrandomized phase II trial of 51 patients with BRAF V600E mutation–positive recurrent or metastatic papillary thyroid cancer that was refractory to RAI investigated the safety and efficacy of vemurafenib. Of these 51 patients, 26 had never received a VEGFR-targeted therapy (cohort 1) and 25 had previously received this class of therapy (cohort 2). The primary end point, best overall response rate
for cohort 1, was 38.5% (95% CI, 20.2–59.4). Grade ≥3 adverse events were reported in 65% of patients in cohort 1 and 68% in cohort 2. In a subset of 14 patients with BRAF V600E–mutant thyroid carcinoma from a phase I study of dabrafenib, 29% showed partial responses and 64% showed at least a 10% decrease. In addition, another study of 10 patients with BRAF V600E–mutant, RAI-refractory papillary thyroid cancer showed that dabrafenib stimulated radiiodine uptake in 60% of patients, suggesting that dabrafenib may sensitize these tumors to RAI therapy. Both of these studies reported that dabrafenib was well tolerated. Additionally, emerging data suggest that anaplastic lymphoma kinase (ALK) inhibitors may be effective in patients with papillary carcinoma who have ALK gene fusion.

In response to these emerging data, the panel added a recommendation for genomic testing to identify actionable mutations for patients with advanced, progressive, or threatening DTC (see PAP-9, page 1433). Panel members commented that molecular testing is particularly important to inform eligibility for clinical trial participation. The panel also voted to add vemurafenib and dabrafenib as treatment options for patients with BRAF mutation–positive DTCs that are locally recurrent, advanced, and/or metastatic, are not surgically resectable, are not amenable to RAI, and are progressing and/or symptomatic (see PAP-9, page 1433). The decision was made to not specify BRAF V600E mutation, because data show that these inhibitors can work for BRAF-activating mutations other than V600E. The panel discussed whether to add the dabrafenib/trametinib combination (discussed for ATC in the following section) as an option for BRAF-mutated DTC, but decided to not add this regimen due to preliminary results from a phase II clinical trial for DTC presented at the 2017 ASCO Annual Meeting that did not show clear improvements compared with dabrafenib alone.

**NIFTP Pathologic Diagnosis**

NIFTP, formerly known as noninvasive encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), is characterized by its follicular growth pattern, encapsulation or clear demarcation of the tumor from adjacent tissue with no invasion, and nuclear features of papillary carcinoma. NIFTP has a low risk for adverse outcomes and, therefore, requires less aggressive treatment. NIFTP was reclassified in 2016 to prevent overtreatment of this indolent tumor type and the psychological consequences of a cancer diagnosis on patients. The College of American Pathologists updated its protocols with NIFTP in the June 2017 version. Per their protocol, reporting is optional because NIFTP is not overtly malignant and only size, laterality, and margin status are reported.

Although molecular diagnostic testing may be useful for diagnosing NIFTP in the future, currently available tests were not validated using NIFTP samples. Studies have shown that NIFTP specimens frequently carry characteristic mutations/alterations, including RAS, PAX8/PPARγ, and/or BRAF (with the exception of the aggressive BRAF V600 mutations), differentiating it from papillary subtypes that more frequently show BRAF V600E and RET/PTC alterations. However, multiple studies investigating the performance of molecular diagnostics for this subtype have reported that most thyroid nodules histologically diagnosed as NIFTP are classified as “suspicious” by GEC, possibly leading to more aggressive surgical treatment than is necessary. Therefore, the validation of molecular diagnostics with NIFTP samples will be necessary to ensure that the tests are accurately classifying these.

The panel members agreed that although NIFTP is still considered a subset of papillary carcinoma, these tumors have low malignant potential and therefore do not require completion thyroidectomy after lobectomy. Based on this, the panel consensus was to conduct no further treatment after lobectomy and histologic diagnosis of NIFTP, and rather to proceed to active surveillance with consideration of thyroglobulin measurement and anti-Tg antibodies 6 to 12 weeks after lobectomy. Levothyroxine therapy may be considered to keep thyroid-stimulating hormone levels low to normal (see PAP-1, page 1432). At the time of the panel meeting, some panel members mentioned that the NIFTP terminology was still in the process of being accepted within practice patterns and that some institutions may still be classifying these tumors as EFVPTC. To address this, they decided to add a footnote clarifying that noninvasive EFVPTC had been reclassified as NIFTP.
Thyroid Carcinoma, Version 2.2018

Systemic Therapy for ATC

ATC is an aggressive undifferentiated tumor, with a disease-specific mortality approaching 100%. Treatment of ATC should be planned in consultation with a multidisciplinary team and ideally performed at a high-volume center with expertise in treating ATC. Therapy is often multimodal, consisting of surgery, systemic therapy, and/or radiation therapy, because ATC often responds poorly to single-modality therapy. Given the poor outcome with current standard therapy, all patients—regardless of surgical resection—should be considered for clinical trials.

Panel members commented that few therapies have emerged for treating ATC over the years. Given the limited available treatments and a very poor prognosis, clinicians are grasping for options for these patients. With this in mind, the panel decided to add a recommendation to conduct molecular testing for actionable mutations in all patients with ATC who are considering systemic therapy (see ANAP-2, page 1434). Panel members agreed that molecular testing is part of the global approach to managing patients with ATC and is strongly recommended. Although there is now an FDA-approved therapy for ATC with the BRAF V600E mutation (discussed in the following paragraph), the panel does not intend for the recommendation regarding molecular testing to only apply to BRAF mutations; any targeted therapies that are effective against an identified mutation/alteration may be considered (eg, crizotinib for ALK mutations).

BRAF mutations have been reported in patients with ATC, supporting the utility of BRAF inhibitors for treatment. An open-label, nonrandomized, multicenter phase II trial evaluated the efficacy and safety of dabrafenib in combination with trametinib for treatment of BRAF V600E–mutated rare cancers (including in a cohort of 16 patients with ATC). The primary end point, confirmed overall response rate, was 69% (95% CI, 41%–89%), with 7 responses ongoing. Although duration of response, progression-free survival, and overall survival were not yet reached, the 12-month estimates were 90%, 79%, and 80%, respectively. The combination was found to be well tolerated as evaluated in 100 patients across 7 rare tumor types; common adverse events included fatigue (38%), pyrexia (37%), and nausea (35%). Based on these data, the FDA approved dabrafenib/trametinib for patients with ATC and BRAF V600E mutations on May 4, 2018.

The panel commented that the survival and response rate reported in this trial were very encouraging, especially for a disease with such a poor prognosis. However, they cautioned that the small size of the ATC cohort (N=16) limited their ability to make a strong recommendation for this regimen. Therefore, the panel drafted a footnote suggesting consideration of dabrafenib/trametinib combination therapy in BRAF V600E mutation–positive ATC (see ANAP-2, page 1434). Several panel members mentioned that their institutions have adopted testing for BRAF mutations and are treating patients with dabrafenib/trametinib when BRAF V600E mutations are detected. Anecdotally, they have noted impressive responses in patients with disease that responds to the therapy. The panel also discussed whether the dabrafenib/trametinib recommendation should be limited to only BRAF V600E, because deep sequencing will often yield multiple actionable mutations in this tumor type. The decision was to specify V600E mutation because there are currently no data to guide how to treat ATC with other mutations. The panel looks forward to additional data with larger numbers of patients showing benefit from this regimen in BRAF-mutated ATC, at which time they may consider strengthening their recommendation. In the meantime, the panel stressed that clinical trial participation should still be the preferred treatment option for patients with ATC who qualify.

Conclusions

Recent medical advances have improved treatment for patients with thyroid cancers through better identification of indolent subtypes that require less aggressive treatment and the development of new targeted therapy options for advanced or metastatic disease. Although the data are not yet strong enough to be considered a standard of care, use of molecular diagnostics for indeterminate FNA results may help some patients with indolent nodules avoid surgery. Likewise, the recent reclassification of the NIFTP subtype allows patients with this low-risk tumor to avoid total thyroidectomy and its associated side effects. However, molecular markers can also inform the use of targeted therapies and/or clinical trial eligibility for advanced or metastatic thyroid carcinoma. This approach is especially promising for ATC, a subtype with poor prognosis and few treatment options.
References


Thyroid Carcinoma, Version 2.2018


Instructions for Completion
To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/84621; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet

Posttest Questions

1. Consideration of molecular diagnostic testing is currently recommended in the NCCN Guidelines for Thyroid Carcinoma for which of the following FNA results?
   a. Carcinoma (malignancy)
   b. Follicular neoplasm or suspicious for follicular neoplasm
   c. AUS or FLUS
   d. A, B, and C
   e. B and C

2. True or False: Based on its low potential for malignancy, noninvasive EFVPTC has been reclassified as NIFTP, and completion thyroidectomy is not recommended for this pathologic diagnosis.

3. Which of the following therapies is recommended in the NCCN Guidelines for treatment of locally advanced or metastatic ATC with BRAF V600E mutation and no satisfactory locoregional treatment options?
   a. Vemurafenib
   b. Encorafenib + binimetinib
   c. Dabrafenib + trametinib
   d. All of the above